Cell Therapy in Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is the most common cause of hospitalisation for heart failure. However, only limited effective treatments are available. Recent evidence suggests that HFpEF may result from a systemic proinflammatory state, microvascular endothelial inflammation...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2022-03-01
|
| Series: | Cardiac Failure Review |
| Online Access: | https://www.cfrjournal.com/articleindex/cfr.2021.21 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849220282517028864 |
|---|---|
| author | Sabina Frljak Gregor Poglajen Bojan Vrtovec |
| author_facet | Sabina Frljak Gregor Poglajen Bojan Vrtovec |
| author_sort | Sabina Frljak |
| collection | DOAJ |
| description | Heart failure with preserved ejection fraction (HFpEF) is the most common cause of hospitalisation for heart failure. However, only limited effective treatments are available. Recent evidence suggests that HFpEF may result from a systemic proinflammatory state, microvascular endothelial inflammation and microvascular rarefaction. Formation of new microvasculature in ischaemic tissues is dependent on CD34+ cells, which incorporate into the newly developing vasculature and produce pro-angiogenic cytokines. In HFpEF patients, worsening of diastolic function appears to correlate with decreased numbers of CD34+ cells. Therefore, it is plausible that increasing the myocardial numbers of CD34+ cells could theoretically lead to improved microvascular function and improved diastolic parameters in HFpEF. In accordance with this hypothesis, recent pilot clinical data suggest that CD34+ cell therapy may indeed be associated with improved diastolic function and better functional capacity in HFpEF patients and could thus represent a promising novel therapeutic modality for this patient population. |
| format | Article |
| id | doaj-art-a83febc5bc3247afb6be928e973ff9d7 |
| institution | Kabale University |
| issn | 2057-7540 2057-7559 |
| language | English |
| publishDate | 2022-03-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | Cardiac Failure Review |
| spelling | doaj-art-a83febc5bc3247afb6be928e973ff9d72024-12-14T16:03:30ZengRadcliffe Medical MediaCardiac Failure Review2057-75402057-75592022-03-01810.15420/cfr.2021.21Cell Therapy in Heart Failure with Preserved Ejection FractionSabina Frljak0Gregor Poglajen1Bojan Vrtovec2Advanced Heart Failure and Transplantation Center, UMC Ljubljana, SloveniaAdvanced Heart Failure and Transplantation Center, UMC Ljubljana, SloveniaAdvanced Heart Failure and Transplantation Center, UMC Ljubljana, SloveniaHeart failure with preserved ejection fraction (HFpEF) is the most common cause of hospitalisation for heart failure. However, only limited effective treatments are available. Recent evidence suggests that HFpEF may result from a systemic proinflammatory state, microvascular endothelial inflammation and microvascular rarefaction. Formation of new microvasculature in ischaemic tissues is dependent on CD34+ cells, which incorporate into the newly developing vasculature and produce pro-angiogenic cytokines. In HFpEF patients, worsening of diastolic function appears to correlate with decreased numbers of CD34+ cells. Therefore, it is plausible that increasing the myocardial numbers of CD34+ cells could theoretically lead to improved microvascular function and improved diastolic parameters in HFpEF. In accordance with this hypothesis, recent pilot clinical data suggest that CD34+ cell therapy may indeed be associated with improved diastolic function and better functional capacity in HFpEF patients and could thus represent a promising novel therapeutic modality for this patient population.https://www.cfrjournal.com/articleindex/cfr.2021.21 |
| spellingShingle | Sabina Frljak Gregor Poglajen Bojan Vrtovec Cell Therapy in Heart Failure with Preserved Ejection Fraction Cardiac Failure Review |
| title | Cell Therapy in Heart Failure with Preserved Ejection Fraction |
| title_full | Cell Therapy in Heart Failure with Preserved Ejection Fraction |
| title_fullStr | Cell Therapy in Heart Failure with Preserved Ejection Fraction |
| title_full_unstemmed | Cell Therapy in Heart Failure with Preserved Ejection Fraction |
| title_short | Cell Therapy in Heart Failure with Preserved Ejection Fraction |
| title_sort | cell therapy in heart failure with preserved ejection fraction |
| url | https://www.cfrjournal.com/articleindex/cfr.2021.21 |
| work_keys_str_mv | AT sabinafrljak celltherapyinheartfailurewithpreservedejectionfraction AT gregorpoglajen celltherapyinheartfailurewithpreservedejectionfraction AT bojanvrtovec celltherapyinheartfailurewithpreservedejectionfraction |